Chimin(SH:603222)2021-04-28 16:00Financial Performance - Operating revenue for the period reached CNY 253,770,979.45, a 92.53% increase year-on-year[6] - Net profit attributable to shareholders was CNY 39,943,254.67, reversing from a loss of CNY 7,307,360.39 in the same period last year[6] - The weighted average return on net assets increased by 5.36 percentage points to 4.52%[6] - Cash flow from operating activities was CNY 24,230,152.87, compared to a negative cash flow of CNY 4,667,291.75 in the same period last year[6] - The company reported a significant increase in operating expenses, with operating costs rising by 53.42% to CNY 132,458,360.10, attributed to the medical device segment[13] - The company reported a net profit of -4,414,385.71 RMB, compared to a net profit of 305,129.52 RMB in Q1 2020, indicating a significant decline in profitability[33] - The comprehensive income for Q1 2021 was CNY 36,806,172.54, compared to a comprehensive loss of CNY 11,555,523.41 in Q1 2020[30] Assets and Liabilities - Total assets increased by 10.17% to CNY 2,525,177,321.06 compared to the end of the previous year[6] - The total current assets reached RMB 998,222,352.21, up from RMB 821,744,573.33 at the end of 2020, indicating a growth of about 21.5%[22] - The total liabilities decreased to RMB 1,203,102,956.10 from RMB 1,245,710,863.56, showing a reduction of approximately 3.4%[23] - The total non-current assets amounted to RMB 1,526,954,968.85, up from RMB 1,470,230,180.65, indicating a growth of approximately 3.9%[22] - Total liabilities decreased from 1,256,228,828.88 RMB at the beginning of 2021 to 1,245,710,863.56 RMB, indicating a reduction in financial obligations[42] Shareholder Information - Net assets attributable to shareholders increased by 31.35% to CNY 1,135,815,609.87 compared to the end of the previous year[6] - The number of shareholders reached 54,738, indicating a broadening of the shareholder base[10] - The equity attributable to shareholders increased to RMB 1,135,815,609.87 from RMB 864,745,057.76, representing a growth of around 31.3%[23] Cash Flow and Financing - The company generated a net cash flow from operating activities of 24,230,152.87 RMB in Q1 2021, a recovery from a negative cash flow of -4,667,291.75 RMB in Q1 2020[35] - The net cash flow from financing activities was 221,090,917.43 RMB, a substantial increase from 3,857,167.18 RMB in Q1 2020, reflecting strong financing efforts[38] - Cash inflow from financing activities included 234,104,302.00 RMB from investment absorption, highlighting strong investor confidence[38] Investments and Acquisitions - Long-term equity investments surged by 716.88% to CNY 704,919.50, attributed to increased investments in subsidiaries[12] - The company is in the process of acquiring 80% of Ezhou Second Hospital, with a pending lawsuit regarding performance compensation from the seller[15] - The company completed a private placement of 20,743,468 shares at a price of CNY 11.63 per share, raising a total of CNY 241,246,532.84[18] Revenue Sources - Operating revenue increased by 92.53% to CNY 253,770,979.45 compared to the previous period, primarily due to increased revenue from the medical device segment[13] - Cash received from sales of goods and services rose by 85.55% to CNY 250,121,202.53, reflecting strong performance in the medical device segment[14] Other Financial Metrics - The company received government subsidies amounting to CNY 840,630.68, which are related to normal business operations[6] - Other income decreased by 45.00% to CNY 792,512.78, primarily due to a reduction in other income sources[13] - The company incurred a credit impairment loss of CNY -2,345,019.65, a significant increase compared to the previous period, indicating higher provisions for bad debts[13]